查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1778476

全球Sirolimus市场：成长、规模和趋势分析 - 按应用、剂量和分销管道 - 区域展望、竞争策略和 2034 年细分市场预测

Global Sirolimus Market Growth, Size, Trends Analysis - By Application, By Dosage, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 260 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

根据《全球Sirolimus市场：成长、规模和趋势分析—按应用、剂量和分销管道—区域展望、竞争策略和 2034 年细分预测》报告，全球Sirolimus市场规模预计到 2034 年将达到 4.1016 亿，复合年增长率为 3.85%。

Sirolimus，又称雷帕霉素，是一种大环内酯类化合物，具有抗真菌和抗肿瘤特性，也是强效免疫抑制剂。它透过抑制免疫系统，使身体能够吸收新器官，从而防止器官移植后出现排斥。Sirolimus也用于冠状动脉支架涂层、预防肾臟移植患者的器官移植排斥反应，以及治疗淋巴管平滑肌瘤病（一种肺部疾病）。

限制因素：全球Sirolimus市场扩张受到多种不良反应的阻碍，包括更容易感染疾病、患有恶性肿瘤、高三酸甘油脂血症血症、高胆固醇症胆固醇血症、血管性水肿、蛋白尿等。由于可能出现高血脂症和肝动脉血栓症等副作用，接受肝臟或肺移植的患者通常不会服用Sirolimus。

调查范围

报告指标详情

市场规模：2021-2034年

基准年：2024年

预测期：2025-2034年

目标细分：依用途、按剂量、按分销管道

涵盖地区：北美、拉丁美洲、亚太地区、欧洲、中东和非洲

目标公司

Accord Healthcare Limited、Apotex Inc、Amneal Pharmaceuticals, Inc、Actiza Pharmaceutical Private Limited、Biocon Limited、Concept Medical、Concord Biotech、Dr. Reddy's Laboratories Ltd、Intas Pharmaceuticals Ltd、丽珠製药集团有限公司

全球Sirolimus市场细分：

依应用：全球Sirolimus市场细分为器官移植排斥、淋巴管肌瘤病以及Sirolimus涂层球囊和导管装置等应用。

依剂量：全球Sirolimus市场分为 0.5 毫克、1 毫克和 2 毫克。

依分销管道：全球Sirolimus市场分为医院药局、零售药局和线上药局。

区域：包括北美、拉丁美洲、亚太地区、欧洲以及中东和非洲的数据。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场动态

  • 驱动因素、限制因素、机会与挑战分析

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争态势

  • 全球Sirolimus市场製造地、分布、销售区域及产品类型
  • 全球Sirolimus市场的併购、合作伙伴关係、产品发布和合作

7. 全球Sirolimus市场，按应用划分（百万美元），2021-2034 年

  • 器官移植排斥
  • 淋巴管平滑肌瘤病（LAM）
  • Sirolimus涂层球囊和导管装置

8. 2021 年至 2034 年全球Sirolimus市场（以剂量计算，百万美元）

  • 0.5mg
  • 1mg
  • 2mg

9. 2021-2034 年全球Sirolimus市场（按分销管道划分）（百万美元）

  • 医院药房
  • 零售药局
  • 网路药局

第 10 章。 2021-2034 年全球Sirolimus市场（百万美元）

  • 全球Sirolimus市场规模与市场占有率

第 11 章。 2021 年至 2034 年按地区分列的全球Sirolimus市场（百万美元）

  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亚
    • 其他的
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他的

第十二章：公司简介

  • Accord Healthcare Limited
  • Apotex Inc
  • Amneal Pharmaceuticals, Inc
  • Actiza Pharmaceutical Private Limited
  • Biocon Limited
  • Concept Medical
  • Concord Biotech
  • Dr. Reddy's Laboratories Ltd
  • Intas Pharmaceuticals Ltd
  • Livzon Pharmaceuticals Group Inc
  • 其他的

第十三章 结论

第 14 章简称列表

第 15 章参考链接

简介目录
Product Code: HLCA25173

Sirolimus Market Introduction and Overview

According to SPER market research, 'Global Sirolimus Market Size- By Application, By Dosage, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Sirolimus Market is predicted to reach 410.16 million by 2034 with a CAGR of 3.85%.

Sirolimus, sometimes referred to as rapamycin, is a macrolide compound that has antifungal and antitumor properties and is a potent immunosuppressant. It works by suppressing the immune system and allowing your body to absorb the new organ, hence preventing rejection of any organs following transplant. Sirolimus is also used to coat coronary stents, prevent organ transplant rejection in patients undergoing renal transplants, and treat Lymphangioleiomyomatosis (lung illness).

Restraints: The expansion of the global sirolimus market is being hindered by a number of negative effects, such as increased susceptibility to infection, malignancy, hypertriglyceridemia, hypercholesterolaemia, angioedema, and proteinuria. Due to potential side effects such hyperlipidaemia and hepatic artery thrombosis, sirolimus is often not given to patients receiving liver and lung transplants.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Application, By Dosage, By Distribution Channel

Regions covered

Accord Healthcare Limited, Apotex Inc, Amneal Pharmaceuticals, Inc, Actiza Pharmaceutical Private

Companies Covered

Accord Healthcare Limited, Apotex Inc, Amneal Pharmaceuticals, Inc, Actiza Pharmaceutical Private Limited, Biocon Limited, Concept Medical, Concord Biotech, Dr. Reddy's Laboratories Ltd, Intas Pharmaceuticals Ltd, Livzon Pharmaceuticals Group Inc

Global Sirolimus Market Segmentation:

By Application: Based on the Application, Global Sirolimus Market is segmented as; Organ Transplant Rejection, Lymphangioleiomyomatosis, Sirolimus coated balloons and catheter devices.

By Dosage: Based on the Dosage, Global Sirolimus Market is segmented as; 0.5mg, 1mg, 2mg.

By Distribution Channel: Based on the Distribution Channel, Global Sirolimus Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online pharmacy.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1.Introduction

  • 1.1.Scope of the report
  • 1.2.Market segment analysis

2.Research Methodology

  • 2.1.Research data source
    • 2.1.1.Secondary Data
    • 2.1.2.Primary Data
    • 2.1.3.SPERs internal database
    • 2.1.4.Premium insight from KOLs
  • 2.2.Market size estimation
    • 2.2.1.Top-down and Bottom-up approach
  • 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

  • 4.1.Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1.Drivers
    • 4.1.2.Restraints
    • 4.1.3.Opportunities
    • 4.1.4.Challenges

5.Market variable and outlook

  • 5.1.SWOT Analysis
    • 5.1.1.Strengths
    • 5.1.2.Weaknesses
    • 5.1.3.Opportunities
    • 5.1.4.Threats
  • 5.2.PESTEL Analysis
    • 5.2.1.Political Landscape
    • 5.2.2.Economic Landscape
    • 5.2.3.Social Landscape
    • 5.2.4.Technological Landscape
    • 5.2.5.Environmental Landscape
    • 5.2.6.Legal Landscape
  • 5.3.PORTERs Five Forces
    • 5.3.1.Bargaining power of suppliers
    • 5.3.2.Bargaining power of buyers
    • 5.3.3.Threat of Substitute
    • 5.3.4.Threat of new entrant
    • 5.3.5.Competitive rivalry
  • 5.4.Heat Map Analysis

6.Competitive Landscape

  • 6.1.Global Sirolimus Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Sirolimus Market

7.Global Sirolimus Market, By Application (USD Million) 2021-2034

  • 7.1.Organ transplant rejection
  • 7.2.Lymphangioleiomyomatosis (LAM)
  • 7.3.Sirolimus coated balloons and catheter devices

8.Global Sirolimus Market, By Dosage (USD Million) 2021-2034

      • 8.1.0.5mg
    • 8.2.1mg
    • 8.3.2mg

9.Global Sirolimus Market, By Distribution Channel (USD Million) 2021-2034

  • 9.1.Hospital pharmacy
  • 9.2.Retail pharmacy
  • 9.3.Online pharmacy

10.Global Sirolimus Market, (USD Million) 2021-2034

  • 10.1.Global Sirolimus Market Size and Market Share

11.Global Sirolimus Market, By Region, (USD Million) 2021-2034

  • 11.1.Asia-Pacific
    • 11.1.1.Australia
    • 11.1.2.China
    • 11.1.3.India
    • 11.1.4.Japan
    • 11.1.5.South Korea
    • 11.1.6.Rest of Asia-Pacific
  • 11.2.Europe
    • 11.2.1.France
    • 11.2.2.Germany
    • 11.2.3.Italy
    • 11.2.4.Spain
    • 11.2.5.United Kingdom
    • 11.2.6.Rest of Europe
  • 11.3.Middle East and Africa
    • 11.3.1.Kingdom of Saudi Arabia
    • 11.3.2.United Arab Emirates
    • 11.3.3.Qatar
    • 11.3.4.South Africa
    • 11.3.5.Egypt
    • 11.3.6.Morocco
    • 11.3.7.Nigeria
    • 11.3.8.Rest of Middle-East and Africa
  • 11.4.North America
    • 11.4.1.Canada
    • 11.4.2.Mexico
    • 11.4.3.United States
  • 11.5.Latin America
    • 11.5.1.Argentina
    • 11.5.2.Brazil
    • 11.5.3.Rest of Latin America

12.Company Profile

  • 12.1.Accord Healthcare Limited
    • 12.1.1.Company details
    • 12.1.2.Financial outlook
    • 12.1.3.Product summary
    • 12.1.4.Recent developments
  • 12.2.Apotex Inc
    • 12.2.1.Company details
    • 12.2.2.Financial outlook
    • 12.2.3.Product summary
    • 12.2.4.Recent developments
  • 12.3.Amneal Pharmaceuticals, Inc
    • 12.3.1.Company details
    • 12.3.2.Financial outlook
    • 12.3.3.Product summary
    • 12.3.4.Recent developments
  • 12.4.Actiza Pharmaceutical Private Limited
    • 12.4.1.Company details
    • 12.4.2.Financial outlook
    • 12.4.3.Product summary
    • 12.4.4.Recent developments
  • 12.5.Biocon Limited
    • 12.5.1.Company details
    • 12.5.2.Financial outlook
    • 12.5.3.Product summary
    • 12.5.4.Recent developments
  • 12.6.Concept Medical
    • 12.6.1.Company details
    • 12.6.2.Financial outlook
    • 12.6.3.Product summary
    • 12.6.4.Recent developments
  • 12.7.Concord Biotech
    • 12.7.1.Company details
    • 12.7.2.Financial outlook
    • 12.7.3.Product summary
    • 12.7.4.Recent developments
  • 12.8.Dr. Reddy's Laboratories Ltd
    • 12.8.1.Company details
    • 12.8.2.Financial outlook
    • 12.8.3.Product summary
    • 12.8.4.Recent developments
  • 12.9.Intas Pharmaceuticals Ltd
    • 12.9.1.Company details
    • 12.9.2.Financial outlook
    • 12.9.3.Product summary
    • 12.9.4.Recent developments
  • 12.10.Livzon Pharmaceuticals Group Inc
    • 12.10.1.Company details
    • 12.10.2.Financial outlook
    • 12.10.3.Product summary
    • 12.10.4.Recent developments
  • 12.11.Others

13.Conclusion

14.List of Abbreviations

15.Reference Links